<DOC>
	<DOCNO>NCT00105300</DOCNO>
	<brief_summary>The goal study test whether adalimumab induce clinical remission subject active Crohn 's disease initially treat infliximab either lose response discontinue use result intolerance drug .</brief_summary>
	<brief_title>Study Human Anti-TNF Monoclonal Antibody Adalimumab Induction Clinical Remission Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Males female age 18 75 diagnosed mild moderate Crohn 's disease ( define CDAI [ Crohn 's Disease Activity Index ] score 220 450 ) Normal lab parameter Are willing give inform consent Have previously use either intolerant lose response infliximab History certain type cancer Diagnosis ulcerative colitis Pregnant female breast feeding subject Known obstructive stricture Surgical bowel resection past 6 month History listeria , human immunodeficiency virus ( HIV ) , central nervous system demyelinate disease untreated TB ( tuberculosis ) History poorly control medical condition Specific dos duration Crohn 's medication Subjects previously use infliximab never clinically respond unless primary nonresponse due treatment limit reaction infliximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>